

To the Press:

Exiqon A/S Skelstedet 16 2950 Vedbæk Denmark

Phone: +45 4566 0888 Fax: +45 4566 1888 exiqon@exiqon.com www.exiqon.com CVR/Tax Id: 18 98 44 31

6 December 2010

Exiqon releases new 6th generation microRNA array with the broadest and most updated coverage of miRBase on the market

Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression analysis products, today announced the launch of the 6th generation of miRCURY LNA[™] microRNA Arrays for expression profiling of microRNA from human, mouse and rat.

The new microRNA arrays have 2361 unique capture probes covering all mature human (1223), mouse (1055), rat (680) and related viral (human 146, mouse 57) microRNA sequences as annotated in miRBase v16.0. This is an increase of 500 microRNA capture probes compared with the 5th generation microRNA Array. The array also contains capture probes for 66 proprietary miRPlus[™] microRNAs.

"With the new and updated array we strengthen our position as the leading provider of microRNA products", said Vice President Sales & Marketing Henrik M. Pfundheller and added: "Our 6th generation microRNA array offers by far the broadest and most updated coverage of miRBase 16 on the market with capture probes for more than 25% additional human microRNA compared to our competitors".

The miRCURY LNA[™] microRNA Array, 6th gen - hsa, mmu & rno microarray, is the most sensitive microRNA array available today with required sample input of as little as 30 ng of total RNA. It is possible to detect down to 10 copies of microRNAs from a biological sample.

Exiqon also recently announced the selection of its microRNA array by a multinational company as the most sensitive and specific platform compared to a main competitor.

The 6th generation of miRCURY LNA[™] microRNA Arrays are fully compatible with Exiqon's miRCURY LNA[™] Universal RT microRNA PCR product line which customers use to validate expression profiles obtained by the miRCURY LNA[™] microRNA Arrays.

Exiqon offers a complete range of products for the microRNA profiling using microarrays including arrays, ready-to-spot probe sets, buffers, labeling kits and software. The arrays are also accessible via Exiqon Services.

Information about the new 6th generation microRNA Array is available here: http://www.exiqon.com/array

View previous press release dated 1 November 2010 regarding selection of Exiqon's array as preferred platform by a multinational company: <u>http://www.exiqon.com/investor/portal</u>

Additional information:

Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101) Henrik M. Pfundheller, VP Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090 2106)

About Exigon

Exiqon's products are based on the proprietary LNA[™] technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on miRNA as biological markers. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.

